10X Genomics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 50 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 20.29.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of 10X Genomics Inc is 7.17, ranking 83 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 166.03M, representing a year-over-year increase of 0.61%, while its net profit experienced a year-over-year increase of 66.85%.
Key Metrics
The current valuation score of 10X Genomics Inc is 8.21, ranking 39 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -56.75, which is -90.28% below the recent high of -5.52 and -16.81% above the recent low of -66.29.
The current earnings forecast score of 10X Genomics Inc is 6.89, ranking 159 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 16.00, with a high of 20.00 and a low of 14.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of 10X Genomics Inc is 6.99, ranking 55 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 23.44 and the support level at 16.04, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of 10X Genomics Inc is 10.00, ranking 1 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 108.13%, representing a quarter-over-quarter increase of 5.55%. The largest institutional shareholder is The Vanguard, holding a total of 12.99M shares, representing 11.04% of shares outstanding, with 10.58% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 10X Genomics Inc is 4.85, ranking 94 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 2.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
